11 results on '"Arhin, Francis"'
Search Results
2. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
- Author
-
Arhin FF, Sarmiento I, and Moeck G
- Subjects
- Acetamides pharmacology, Daptomycin pharmacology, Gene Expression, Linezolid, Lipoglycopeptides, Methicillin-Resistant Staphylococcus aureus genetics, Methicillin-Resistant Staphylococcus aureus growth & development, Methicillin-Resistant Staphylococcus aureus isolation & purification, Microbial Sensitivity Tests, Microbial Viability drug effects, Oxazolidinones pharmacology, Vancomycin pharmacology, Anti-Bacterial Agents pharmacology, Bacterial Proteins genetics, Glycopeptides pharmacology, Methicillin Resistance genetics, Methicillin-Resistant Staphylococcus aureus drug effects
- Abstract
Meticillin-resistant Staphylococcus aureus (MRSA) is routinely detected by amplification of the mecA gene. Recently, MRSA isolates harbouring a novel mec gene (mecC) that is not detected by mecA amplification have been reported. In this study, the activities of the lipoglycopeptide oritavancin as well as the comparators vancomycin, daptomycin and linezolid against 14 mecC MRSA isolates were studied by broth microdilution minimum inhibitory concentration (MIC) and time-kill assays at clinically relevant concentrations of each antibacterial agent. Oritavancin, vancomycin, daptomycin and linezolid MIC90 values (MIC required to inhibit 90% of the isolates) against the mecC isolates were 0.06, 1, 1 and 2mg/L, respectively. In time-kill assays, oritavancin at concentrations reflective of its free peak in plasma of patients receiving a single 1200 mg intravenous dose and the level 24h thereafter was bactericidal against all isolates tested, attaining 3 log kill relative to the starting inoculum between 5 min and 15 min. Vancomycin both at its free peak and free trough concentrations was also bactericidal against all isolates, attaining bactericidal activity between 6h and 24h. Daptomycin was bactericidal only at its free peak concentration, attaining bactericidal activity between 30 min and 4h against the tested isolates. Linezolid was bacteriostatic (<3 log kill relative to the starting inoculum) against the tested isolates. Oritavancin's in vitro activity against mecC MRSA isolates was indistinguishable from that against mecA MRSA isolates both in MIC and time-kill assays., (Copyright © 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
3. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).
- Author
-
Arhin FF, Sarmiento I, and Moeck G
- Subjects
- Humans, Lipoglycopeptides, Staphylococcal Skin Infections microbiology, Anti-Bacterial Agents pharmacology, Drug Resistance, Bacterial, Glycopeptides pharmacology, Methicillin-Resistant Staphylococcus aureus drug effects, Microbial Sensitivity Tests standards, Staphylococcus aureus drug effects, Vancomycin pharmacology
- Published
- 2013
- Full Text
- View/download PDF
4. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
- Author
-
Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, and Moeck G
- Subjects
- Analysis of Variance, Area Under Curve, Clinical Trials, Phase III as Topic, Colony Count, Microbial, Culture Media, Drug Dosage Calculations, Humans, Infusion Pumps, Lipoglycopeptides, Methicillin-Resistant Staphylococcus aureus growth & development, Microbial Sensitivity Tests, Staphylococcal Infections drug therapy, Staphylococcal Infections microbiology, Anti-Bacterial Agents pharmacology, Daptomycin pharmacology, Glycopeptides pharmacology, Methicillin-Resistant Staphylococcus aureus drug effects, Models, Biological, Vancomycin pharmacology
- Abstract
The safety and efficacy of a single 1,200-mg dose of the lipoglycopeptide oritavancin are currently being investigated in two global phase 3 studies of acute bacterial skin and skin structure infections. In this study, an in vitro pharmacokinetic/pharmacodynamic model was established to compare the free-drug pharmacodynamics associated with a single 1,200-mg dose of oritavancin to once-daily dosing with daptomycin at 6 mg/kg of body weight and twice-daily dosing with vancomycin at 1,000 mg against three methicillin-resistant Staphylococcus aureus (MRSA) strains over 72 h. The area under the bacterial-kill curve (AUBKC) was used to assess the antibacterial effect of each dosing regimen at 24 h (AUBKC(0-24)), 48 h (AUBKC(0-48)), and 72 h (AUBKC(0-72)). The rapid bactericidal activities of oritavancin and daptomycin contributed to lower AUBKC(0-24)s for the three MRSA strains than with vancomycin (P < 0.05, as determined by analysis of variance [ANOVA]). Oritavancin exposure also resulted in a lower AUBKC(0-48) and AUBKC(0-72) against one MRSA strain and a lower AUBKC(0-48) for another strain than did vancomycin exposure (P < 0.05). Furthermore, daptomycin exposure resulted in a lower AUBKC(0-48) and AUBKC(0-72) for one of the MRSA isolates than did vancomycin exposure (P < 0.05). Lower AUBKC(0-24)s for two of the MRSA strains (P < 0.05) were obtained with oritavancin exposure than with daptomycin. Thus, the antibacterial effect from the single-dose regimen of oritavancin is as effective as that from either once-daily dosing with daptomycin or twice-daily dosing with vancomycin against the MRSA isolates tested in an in vitro pharmacokinetic/pharmacodynamic model over 72 h. These results provide further justification to assess the single 1,200-mg dose of oritavancin for treatment of acute bacterial skin and skin structure infections.
- Published
- 2013
- Full Text
- View/download PDF
5. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates.
- Author
-
Arhin FF, Kurepina N, Sarmiento I, Parr TR Jr, Moeck G, and Kreiswirth B
- Subjects
- Bacterial Typing Techniques, Genes, Bacterial, Genetic Variation, Genotype, Humans, Lipoglycopeptides, Methicillin-Resistant Staphylococcus aureus classification, Methicillin-Resistant Staphylococcus aureus genetics, Methicillin-Resistant Staphylococcus aureus isolation & purification, Microbial Sensitivity Tests, Anti-Bacterial Agents pharmacology, Community-Acquired Infections microbiology, Glycopeptides pharmacology, Methicillin-Resistant Staphylococcus aureus drug effects, Staphylococcal Infections microbiology
- Published
- 2010
- Full Text
- View/download PDF
6. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
- Author
-
Vaudaux P, Huggler E, Arhin FF, Moeck G, Renzoni A, and Lew DP
- Subjects
- Ciprofloxacin pharmacology, Erythromycin pharmacology, Hospitals, Teaching, Humans, Lipoglycopeptides, Methicillin-Resistant Staphylococcus aureus isolation & purification, Microbial Sensitivity Tests, Switzerland, Vancomycin pharmacology, Anti-Bacterial Agents pharmacology, Bacteremia microbiology, Glycopeptides pharmacology, Methicillin-Resistant Staphylococcus aureus drug effects, Staphylococcal Infections microbiology
- Abstract
In this study, we assessed by broth microdilution the in vitro activity of oritavancin, a semisynthetic lipoglycopeptide currently under development, against selected meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates (n=56) from Geneva University Hospital, Switzerland, displaying a wide range of vancomycin minimum inhibitory concentrations (MICs) (0.25-4 microg/mL). The MRSA resistance phenotype was confirmed by broth microdilution (oxacillin MIC > or = 4 microg/mL) for all isolates; 89% and 100% of the tested isolates were also resistant to erythromycin and ciprofloxacin, respectively. For 53 MRSA isolates for which vancomycin MICs were in the susceptible range (0.5-2.0 microg/mL), the oritavancin MICs ranged from 0.03 microg/mL to 0.5 microg/mL. For these 53 vancomycin-susceptible isolates, the cumulative distribution of oritavancin MICs was markedly different from those of vancomycin, teicoplanin, daptomycin and linezolid MICs, yielding an oritavancin MIC for 90% of the organisms (MIC(90)) (0.25 microg/mL) that was four times lower than the MIC(90) values (1 microg/mL) of comparators. For three MRSA isolates with a vancomycin-intermediate phenotype (vancomycin MIC=4 microg/mL), oritavancin MICs (0.5-1.0 microg/mL) were 2-4-fold lower than vancomycin, teicoplanin or daptomycin MICs, but were equivalent to linezolid MICs. Pairwise comparison for each bloodstream isolate showed that oritavancin was > or =4-fold more active than vancomycin, teicoplanin and daptomycin, against 86%, 75% and 59% of all MRSA isolates, respectively.
- Published
- 2009
- Full Text
- View/download PDF
7. In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020.
- Author
-
Kempf, Marie, Arhin, Francis F, Kuraieva, Alona, and Utt, Eric
- Subjects
GRAM-positive bacteria ,CEFTAROLINE ,STREPTOCOCCUS pneumoniae ,METHICILLIN-resistant staphylococcus aureus ,ANTI-infective agents ,MICROBIAL sensitivity tests ,STAPHYLOCOCCUS aureus - Abstract
Purpose: To assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates of Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, and coagulase-negative staphylococci (CoNS) from blood collected in Africa and Middle East (AfME), Asia Pacific (APAC), Europe, Latin America (LATAM), and North America from 2017 to 2020 as a part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program.Methods: Susceptibility and minimum inhibitory concentration were determined using broth microdilution for all antimicrobial agents by a central reference laboratory according to the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.Results: Ceftaroline showed good activity (susceptibility ≥ 89.8%, MIC
90 0.008– 2 mg/L) against all Gram-positive isolates tested. All isolates of methicillin-susceptible S. aureus, penicillin-susceptible S. pneumoniae, S. agalactiae, S. dysgalactiae, and S. pyogenes were susceptible to ceftaroline (MIC90 0.008– 0.25 mg/L). Ceftaroline susceptibility for MRSA isolates was 89.8% globally (MIC90 2 mg/L). Among the comparator agents, all isolates were susceptible to vancomycin, except S. epidermis (susceptibility, 99.9%). Among other agents, daptomycin, linezolid, and tigecycline showed potent activity (susceptibility ≥ 97.9%, MIC90 0.03– 2 mg/L) against all isolates tested.Conclusion: Ceftaroline showed potent in vitro activity against global bloodstream isolates of Gram-positive bacteria collected between 2017 and 2020. Monitoring and surveillance of global as well as regional longitudinal trends of resistance rates among Gram-positive isolates causing bloodstream infections are important to limit the spread of AMR, establish stewardship measures, and manage and appropriately treat infections. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
8. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
- Author
-
Corey, G. Ralph, Arhin, Francis F., Wikler, Matthew A., Sahm, Daniel F., Kreiswirth, Barry N., Mediavilla, José R., Good, Samantha, Fiset, Claude, Jiang, Hai, Moeck, Greg, Kabler, Heidi, Green, Sinikka, and O'Riordan, William
- Subjects
- *
METHICILLIN-resistant staphylococcus aureus treatment , *METHICILLIN-resistant staphylococcus aureus , *GLYCOPEPTIDES , *DRUG dosage , *PATHOGENIC bacteria , *PATIENTS , *THERAPEUTICS - Abstract
Oritavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The phase 3 studies SOLO I and SOLO II demonstrated comparable efficacy and safety of a single dose of oritavancin compared with 7–10 days of twice-daily vancomycin in adults with acute bacterial skin and skin-structure infections (ABSSSIs). The present analysis assessed clinical responses by pathogen at 48–72 h and at study days 14–24 in SOLO patients within the pooled data set. Of the 1959 patients in the pooled SOLO studies, 1067 had at least one baseline Gram-positive pathogen and 405 had MRSA. Clinical response rates were similar for oritavancin- and vancomycin-treated patients by pathogen, including Staphylococcus aureus with or without the Panton–Valentine leukocidin ( pvl ) gene and from different clonal complexes, and were similar for pathogens within each treatment group. Oritavancin exhibited potent in vitro activity against all baseline pathogens, with MIC 90 values (minimum inhibitory concentration required to inhibit 90% of the isolates) of 0.12 µg/mL for Staphylococcus aureus , 0.25 µg/mL for Streptococcus pyogenes and 0.06 µg/mL for Enterococcus faecalis . Whereas both oritavancin and vancomycin achieved similarly high rates of clinical response by pathogen, including methicillin-susceptible and -resistant Staphylococcus aureus , oritavancin provides a single-dose alternative to 7–10 days of twice-daily vancomycin to treat ABSSSIs. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus
- Author
-
Arhin, Francis F., Sarmiento, Ingrid, Parr, Thomas R., and Moeck, Gregory
- Subjects
- *
STAPHYLOCOCCUS aureus infections , *VANCOMYCIN , *ANTIBACTERIAL agents , *INFECTIVE endocarditis , *METHICILLIN-resistant staphylococcus aureus , *BACTERICIDAL action , *MICROBIAL growth - Abstract
Abstract: In this study, the impact of inoculum density on the growth inhibitory and killing activities of oritavancin and comparators (vancomycin, daptomycin and linezolid) in vitro against four Staphylococcus aureus strains at clinically relevant drug concentrations was studied. Broth microdilution and time–kill assays were performed using a standard inoculum [ca. 105 colony-forming units (CFU)/mL as per Clinical and Laboratory Standards Institute (CLSI) guidelines] and a high inoculum (ca. 107 CFU/mL). Whereas minimal inhibitory concentrations (MICs) of comparators were 2–8-fold higher when tested at high inoculum, oritavancin MICs were 16-fold higher for all strains at the high inoculum relative to the standard inoculum. However, in time–kill assays, when tested at its fCmin [trough concentration of free (non-protein-bound) drug] and fCmax (peak concentration of non-protein-bound drug), oritavancin retained its bactericidal activity against a vancomycin-susceptible, meticillin-susceptible S. aureus (VS-MSSA) strain and a vancomycin-susceptible, meticillin-resistant S. aureus (VS-MRSA) strain both at standard and high inocula. At its fCmax, oritavancin was bactericidal at standard inoculum but not at high inoculum against two vancomycin-intermediate S. aureus (VISA) strains. Against both VISA strains at standard inoculum, oritavancin at its fCmin reduced cell density by between 2 and 3log (bacteriostatic), predicting that it will retain activity against certain VISA infections. However, oritavancin had no substantial growth inhibitory effect against either VISA strain at high inoculum, suggesting that in rare VISA infections with an anticipated high bacterial burden such as endocarditis, alternative oritavancin dosing strategies, including combinations with other agents, may be explored. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
10. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
- Author
-
Sweeney, Debora, Shinabarger, Dean L., Arhin, Francis F., Belley, Adam, Moeck, Greg, and Pillar, Chris M.
- Subjects
- *
METHICILLIN-resistant staphylococcus aureus , *BACTERICIDES , *GLYCOPEPTIDES , *MEROPENEM , *PUBLIC health , *IN vitro studies - Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a threat to the public health due to their prevalence and associated mortality and morbidity. Several agents have been recently approved to treat MRSA skin infections including lipoglycopeptides (dalbavancin, oritavancin, and telavancin), ceftaroline, and tedizolid. This study compared the MIC, minimum bactericidal concentration (MBC), and time-kill of these agents alongside daptomycin, linezolid, and vancomycin against MRSA (n = 15); meropenem, cefazolin, and nafcillin were also included against methicillin-susceptible S. aureus (MSSA [n = 12]). MIC and MBC testing was conducted in accordance with Clinical and Laboratory Standards Institute guidelines, and time-kills were evaluated at multiples of the MIC and the free-drug maximum plasma concentration ( f C max ) at both standard and high inoculum densities for a subset of MRSA (n = 2) and MSSA (n = 2). MRSA and MSSA were highly susceptible to all agents, with the lipoglycopeptides having the most potent activity by MIC 50/90 . All agents excluding tedizolid and linezolid were bactericidal by MBC for MRSA and MSSA, though dalbavancin and telavancin exhibited strain-specific bactericidal activity for MRSA. All agents excluding tedizolid and linezolid were bactericidal by time-kill at their respective f C max against MRSA and MSSA at standard inoculum density, though oritavancin exhibited the most rapid bactericidal activity. Oritavancin and daptomycin at their respective f C max maintained similar kill curves at high inoculum density. In contrast, the killing observed with other agents was typically reduced or slowed at high inoculum density. These data demonstrate the rapid bactericidal activity of oritavancin and daptomycin against S. aureus relative to other MRSA agents regardless of bacterial burden. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015.
- Author
-
Karlowsky, James A., Walkty, Andrew J., Baxter, Melanie R., Arhin, Francis F., Moeck, Gregory, Adam, Heather J., and Zhanel, George G.
- Subjects
- *
GRAM-positive bacterial infections , *HOSPITAL laboratories , *ANTI-infective agents , *DIAGNOSTIC specimens , *METHICILLIN-resistant staphylococcus aureus - Abstract
Gram-positive bacterial pathogens isolated from patient specimens submitted to 15 Canadian hospital laboratories from 2011 to 2015 were tested in the coordinating laboratory for susceptibility to oritavancin and comparative antimicrobial agents using the Clinical and Laboratory Standards Institute M07-A10 (2015) broth microdilution method. Oritavancin's in vitro activity was equivalent to, or more potent than, vancomycin, daptomycin, linezolid, and tigecycline against methicillin-susceptible Staphylococcus aureus ( n = 2680; oritavancin MIC 90 , 0.12 μg/mL; 99.9% oritavancin-susceptible), methicillin-resistant S. aureus ( n = 728; oritavancin MIC 90 , 0.12 μg/mL; 99.7% oritavancin-susceptible), Streptococcus pyogenes ( n = 218; oritavancin MIC 90 , 0.25 μg/mL; 100% oritavancin-susceptible), Streptococcus agalactiae ( n = 269; oritavancin MIC 90 , 0.12 μg/mL; 100% oritavancin-susceptible), and vancomycin-susceptible Enterococcus faecalis ( n = 508; oritavancin MIC 90 , 0.06 μg/mL; 100% oritavancin-susceptible). Oritavancin, dalbavancin, and telavancin demonstrated equivalent in vitro activities (MIC 90 , μg/mL) against 602 isolates of MSSA (0.06, 0.06, 0.06, respectively) and 144 isolates of MRSA (0.12, 0.06, 0.06, respectively) collected in 2015. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.